1 H NMR (400 MHz, D2O) : 8.40 (s, 1H, Ar-H), 7.71-7.76 (m, 1H, Ar-H), 7.61 (d, J=6.5, 1H, Ar-H), 6.83-6.86 (m, 1H, Ar-H), 6.75 (app t, J=6.5, 1H, Ar-H), 6.05 (d, J=3.6, 1H, 1'-H), 4.61 (app t, J= 3.6, 1H, 2'-H), 4. 2H, CH and CHaHb) , 3.80-3.82 (m, 1H, CH), 3.68 (d J=14.3, 1H, CHaHb), 3.63 (1H, td, J=6.1, 2.6, CH) 3. 4H, and 2xCH2) , 3.00-3.12 (m, 3H, CH2 and CHaCHb), 2.00-2.13 (m, 4H, 2xCH2); 13 C NMR (100 MHz, D2O) C : 152.3, 149.8, 147.8, 144.5, 143.8, 143.2, 134.8, 119.1, 112.7, 90.3, 77.5, 73.2, 71.4, 58.9, 51.10, 51.07, 48.9, 38.6, 36.4, 21.8, 21.3 ; HRMS (ESI+) m/z: (M+H + ) calcd C21H31N9O3 + 458.2623, found 458.2623. 10 (S)-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(3-(pyridin-2ylamino)propyl)amino)-2-ammoniobutanoate, chloride salt: [ ] 23 D +20.73 (c 1.0 in H2O); max/cm -1 3441 (N-H), 170.4, 152.2, 149.7, 147.8, 144.4, 143.8, 143.2, 134.8, 119.1, 112.7, 90.3, 78.0, 73.1, 71.4, 54.7, 51.1, 50.9, 50.8, 50.5, 38.6, 24.1, 21.9 ; HRMS (ESI+) m/z: (M+H + ) calcd C22H31N9O5 + 502.2520, found 502.2521.
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Supplementary Tables
Inhibitor [CARM1 Table S1 . Crystallisation conditions for CARM1-inhibitor complexes.
The protein concentrations indicated are the concentrations measured prior to addition of a half-volume of 500 µM ligand solution, then mixing with the well solution, as detailed in the main text. 4 5 6 7 8 9 10 
